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BACGROUND
Acute renal failure in neonate is a condition of a rapid
impairment of renal function with diminishing of
glomerullar filtration rate. This leads to disturbance in
organic fluid homeostasis and is often associated with
oliguric or anuric stage. Usually (in about 75% of cases)
it appears as prerenal insufficiency connected with the
decrease of blood flow in the kidneys, hypotension and
anoxia [1,2]. It may also be secondary to thrombosis of
renal vessels, disseminated intravascular coagulation
(DIC), necrotizing enterocolitis (NEC), and frequently
occurs in sepsis. Naturally, it complicates the course,
worsen prognosis of above- mentioned illnesses and
increases mortality rate.
Eradication of primary condition, which in turn leads to
ARF, as well as volume expansion, compensation in
electrolytic balance, dilatation of renal vessels are crucial
for therapy [3].
Having known the pathophysiology of ARF, one realises
that improving the renal perfusion by dilating afferent
arterioles in cortex prevents acute tubular necrosis [4].
Drugs, which counteract the constriction of small vessels
in renal cortex, caused by diminution in blood flow and
hypoxia, have tremendous value in the therapy. That is
the reason of using dopamine, although, it has been
shown recently, that so-called ‘splanchnic dose’ is not
efficient in dilating renal arterioles [5,6]. Fenoldopam –
a new analogue of dopamine, used meanwhile in hyper-
tension and prophylaxis of ARF in adults undergoing
cardiac surgery was proved to be more effective [7]. In
the dose 0.1 µg × kg–1 × min–1 it does not show hypoten-
sive effect, while it improves blood supply especially in
the perimedullar area of renal cortex.
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Summary
Background: Fenoldopam – a dopamine analogue – stimulates postsynaptic D1 receptors in the renal and splanchnic circulatory ves-
sels and has no activity on D2 receptors, α and β adrenergic receptors. It increases RBF and urine output, without significant
changes in the blood pressure. Due to those effects, we decided to use fenoldopam in the treatment of infants with acute renal failure
in oliguric state.
Case report: We present the schedule of the therapy of three premature newborns, whom we administered fenoldopam (dose 0.1 µg ×
kg–1 × min–1) in ARF. We observed the improvement in kidney function and urinary output. The first patient suffered from ARF sec-
ondary to SIRS and the abdominal aortic embolism. A recovery of renal function and improvement of clinical state have been
observed after introduction of a complex therapy including fenoldopam).
Next patient developed ARF on the third day after delivery. The inborn infection, hepatic failure, and dyspnoea have accompanied
ARF. Although he was given a complete treatment and fenoldopam infusion leading to increase in diuresis, he died in the course of
DIC.
In the third infant sepsis was the cause of arising ARF on 19th day of life. Two days of using fenoldopam resulted in enlarging uri-
nary output and return of renal function.
Conclusions: The normalisation of renal parameters depended on the combination of traditional methods of therapy with the adminis-
tration of fenoldopam. The positive effects of the therapy indicate the safety of usage and proposed dosage of fenoldopam in infants
and should be verified in further studies.
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The latter effect of fenoldopam seems to be important
in premature children, whose perimedullar glomerulli
are earlier mature but more susceptible to anoxia [2].
Up to this moment, we have not found any report about
this drug administrating to premature infants.
CASE REPORT
Case 1
The first patient, a premature male infant, with birth-
weight 1390 g, was delivered by caesarean section
because of premature rupture of membranes) (PROM),
after 29 weeks of pregnancy. He gained 7 points in 1
min in the Apgar score. Because of the severe dyspnoea
the baby was intubated, ventilated with respirator.
Surfactant was administrated within the first day of life.
Starting from the second day of life, the breath was sup-
ported with the nCPAP system. On the day fourth the
clinical condition of the infant deteriorated. The neonate
required mechanical ventilation. We observed a sudden
impairment of peripheral perfusion in the area of lower
limbs and anuria. On the ground of the clinical status
and laboratory investigations (results found on the 2nd
day of life: PTINR 1.2; aPTT 133sec; plasma fibrinogen
level – 3.6 g × l–1. results found on the 4th day of life:
Antitrombin III 24%, leucocytosis 24×103) thrombotic
syndrome was suspected. A catheter was removed from
umbilical artery. Heparin (100 iu × kg–1 × 6 h–1), antibiot-
ic (meropenem), infusion of dopamine with dobutamine
(5 µg × kg–1 × min–1) and sufentanyl were administered.
The infant was also supplemented with antitrombin III.
We monitored fluid balance, but within the next 24
hours no diuresis was observed. Data of laboratory
analyses revealed further deterioration in hemostasis,
lowering of hematocrit, changes in systemic inflamma-
tion indicators. Blood test values were as follows: Hb
11.7 g × dl–1; Hct 23.3%; RBC 3.23×106 ; WBC 4.93×103,
PLT 198×103; aPTT 61.8 sec; fibrinogen 1.03 g × l–1; D-
dimers 8304 u × l–1; AT III 154%; protein C 2%; elec-
trolytes serum level (mmolxl-1): Na 143; K 5, 7; Ca 2,
08; Ca2+ 1, 21; urea serum level (BUN)- 6.6 mmol × l–1.
Then, fresh frozen plasma, erythrocyte mass, 20%
human albumin, pentaglobin and pentoxifylline were
introduced.
Despite this therapy, during the 6th day of life there was
no increase in diuresis and potassium serum level
increased from 6.7 to 10.2 mmol × l–1 as well as plasma
creatinine level was 125 µmol × l–1. Because of the dis-
turbances found in ECG, glucose and insulin infusion,
followed by infusion with salbutamol was started. Then,
peritoneal dialysis was introduced and continued dur-
ing the next 9 days. Administration of erythrocyte mass,
albumin, furosemid, catecholamine were indispensable
(Hb 8.2 g × dl–1; Hct 24.3%; RBC 2.47×106; WBC
3.66×103, PLT 6, 9×103; alb 16.9 g × l–1). Further investi-
gations suggested the diagnosis of SIRS (procalcitonin
>10 ug/l, IL 6 124 u/l, negative blood culture examina-
tion). On the 7th day of life after obtaining informed
consent from the parents, we added fenoldopam (0,1 µg
× kg–1 × min–1) to the therapy. Both diuresis (Figure 1,
series 1), and other parameters (creatinine serum level:
93, 86; 75; 38 µmol × l–1; BUN: 17, 6; 16; 11, 9; 7, 2
mmol × l–1; potassium serum level 5, 2; 4, 2; 4, 1 mmol ×
l–1) of renal function improved on the next two days.
Ultrasound examination performed on 6th and 10th day
of life revealed significant enlargement and blurred
structure of kidneys and the presence of embolus under
renal arteries ostiums (in reversed Doppler image),
whereas on 37th day it presented only faded medullar-
cortical border.
Case 2
Our next patient was a male, SGA (small for gestational
age) premature newborn, delivered via caesarean sec-
tion after 28 weeks of pregnancy. The Apgar score was
6 in the first minute of life. The respiratory distress syn-
drome developed and ventilatory support was intro-
duced. Also, surfactant was instilled. On the ground of
clinical state and extremely low birth-weight (540 g) as
well as obstetrical anamnesis (significant intrauterine
growth retardation and PROM), we suspected the
inborn infection. This hypothesis was partially proved
by the following data of laboratory analysis: increased of
plasma CRP level – 10.6 mg × l–1, PLT 49×103, Hb 14.6
g × dl–1; Hct 43.7%; RBC 3.38×106; WBC 2, 83×103. On
the second day of life significant deterioration in clinical
condition was found. Pulmonary bleeding, and anuria
(0.2 ml urine × kg–1 × h–1) were observed. It was corre-
lated with the changes in plasma urea (4.0–5.2 mmol ×
l–1) and creatinine (64–72 µmol × l–1) concentrations.
The following aberrations in blood cell counts and para-
meters of hemostasis were found: HCT 22.5%; Hb 7, 5
g/dl; RBC 1.74×106; WBC 22.5×103; PLT 28×103, PT
INR 1.86; aPTT 81.7 sec; fibrinogen 0.79 g × l–1; D-
dimers 1080, protein C 3%; ATIII 10.5%. Then, FFP,
ATIII, ceprotin, ampiciline+sulbactam (unasyn), tobra-
mycine, albumin, furosemid, dopamine (2.5 µg × kg–1 ×
min–1) were given. In order to enlarge urinary output
(anuria 1.7ml of urine × kg–1 × h–1) we administered
fenoldopam. The improvement in diuresis rate is pre-
sented in Figure 1. Nevertheless, because of liver insuf-
ficiency, DIC, haematological disorders (Hb 8.4 g × dl–1;
HCT 24%; RBC 2.17×106; WBC 25.5×103; PLT 54×103;
ATIII 39%) and despite of fluid infusion, inotropic and
vasopressor support the infant died.
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Fugure 1. The rate of diuresis in three patients during treatment. Arrow
indicates start of fenoldopam therapy.
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Case 3
In the third case, premature (27+5 weeks of pregnancy)
female twin, delivered via caesarean section, whose Apgar
score was estimated for 6 points, with birth weight 710 g,
ARF occurred in the course of sepsis on the 19th day of
life. During the first few days the neonate needed a sup-
port of nCPAP and applying of surfactant, antibiotics
(unasyn+tobramicyne – CRP 23–41 mg × l–1) and ery-
throcytes concentrate because of anaemia. The clinical
status of the girl was stabilized; she could breathe sponta-
neously for another three days. However, on the 19th day
some episodes of dyspnoea and impairment of peripheral
perfusion was observed. The infant needed ventilatory
support with a respirator. The laboratory investigation
results were as follows: Hct 30, 6%; Hb 10.5 g × dl–1; RBC
3.22×106; WBC 9.9×103; PLT 20.6×103; CRP 31.7; potas-
sium level 4.6 mmol × l–1; BUN 2.7 mmol × l–1; creatinine
serum level 46 × mol × l–1, hemostatic indexes: ATIII
43%; protein C 39%; PT INR 1.1; aPTT 106.2; fibrino-
gen 3.5 g × l–1. Urinary output was 1.45 ml × kg–1 × min–1.
Enterococcus faecalis was found in blood culture and
Acinetobacter cacoaceticus baumani complex in tracheal
aspiration culture. The girl was treated with unasyn.
Then on the ground of blood culture results it was
changed for vancomycine. Also, dobutamine (5 µg × kg–1
× min–1), aminofilline, and fenoldopam were introduced.
The increase in diuresis (from 2.06 ml × kg–1 × h–1 to 4.4
ml × kg–1 × h–1) on the first day of Fenoldopam adminis-
tration was found (Figure 1 series 3). At the moment the
infant is still being hospitalised.
DISCUSSION
Acute renal failure is life threatening clinical condition
in newborn infants.
Premature infants suffer most often from the prerenal type
of ARF, in which the dysfunction of nephrons is associated
with ischemia [8]. Low renal perfusion pressure and
release of renal vasoconstrictor compounds, such as
endothelin increase the risk of renal ischemia and acute
tubular necrosis. The renal and splanchnic circulatory ves-
sels are very prone to hypoxic insult due to their microvas-
cular anatomy, and they may provide early evidence of
altered oxygen metabolism, changes in mean arterial pres-
sure, cardiac output and volume imbalance [7].
Dopamine was thought to act renoprotective in ‘renal
dose’, but recent studies failed to demonstrate this mech-
anism [9,10]. Moreover, it proved, that dopamine may
constrict the vessels already in a dosis 5 µg × kg–1 × min–1
[11], probably due to its nonselective agonism to D1, α1,
β receptors. That is the reason of searching for another
potent vasodilatators. Fenoldopam, developed by chemi-
cal modification of the dopamine molecule, has specifici-
ty for the postsynaptic D1 receptor with no direct or indi-
rect effects on either α or β receptors. Lack of these
activities is beneficial for renal, mesenteric and coronary
perfusion. Fenoldopam was reported to be 6 times more
effective vasodilatator as dopamine [12]. It improves the
blood flow in renal medulla significantly more than in
renal cortex. The finding connected with the flow rate of
0,1 µg × kg–1 × min–1, revealing good creatinine clearance
not associated with haemodynamic instability [13], enco-
uraged us to administer this medication in described
above three cases. Although, fenoldopam being hypoten-
sive drug, may cause tachycardia, or hypotension), we
did not observe these side effects [14]. In the light of
predominantly favourable reports on fenoldopam pre-
venting ARF in patients undergoing abdominal aortic
aneurysm repair and coronary arteries bypass graft and
information about using this drug in pediatric anaesthe-
sia, we made decision to include fenoldopam to the ther-
apy of ARF [15,16].
We suggest, that improvement in renal function, mea-
sured by urinary output rate, sodium excretion, and
creatinine clearance was partially caused by fenoldopam
infusion. However, the beneficial effects of fenoldopam
in the treatment of ARF should be verified in further
randomised studies.
CONCLUSIONS
1. Fenoldopam can be useful in the treatment of acute
renal failure in premature infants.
2. When given in the dose 0.1 µg × kg–1 × min–1 fenoldo-
pam does not decrease in arterial blood pressure.
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